Evidence for oncolytic virotherapy: Where have we got to and where are we going?

48Citations
Citations of this article
103Readers
Mendeley users who have this article in their library.

Abstract

The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.

Cite

CITATION STYLE

APA

Turnbull, S., West, E. J., Scott, K. J., Appleton, E., Melcher, A., & Ralph, C. (2015, December 2). Evidence for oncolytic virotherapy: Where have we got to and where are we going? Viruses. MDPI AG. https://doi.org/10.3390/v7122938

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free